Literature DB >> 20409512

Prognostic factors and patterns of recurrence in esophageal cancer assert arguments for extended two-field transthoracic esophagectomy.

Justin K Smit1, Bareld B Pultrum, Hendrik M van Dullemen, Gooitzen M Van Dam, Henk Groen, John T M Plukker.   

Abstract

BACKGROUND: High recurrence rates determine the dismal outcome in esophageal cancer. We reviewed our experiences and defined prognostic factors and patterns of recurrences after curatively intended transthoracic esophagectomy.
METHODS: Between January 1991 and December 2005, 212 consecutive patients underwent a radical transthoracic esophagectomy with extended 2-field lymphadenectomy. Recurrence rates, survival, and prognostic factors were analyzed (minimal follow-up period, 2 y).
RESULTS: Radicality was obtained in 85.6%. The median follow-up period was 26.6 months. The overall recurrence rate at 1, 3, and 5 years was 28%, 44%, and 64%, respectively, and locoregional recurrence rate was 17%, 27%, and 43%, respectively. Overall survival rates, including postoperative deaths, were 45% and 34% at 3 and 5 years, respectively. pT stage and lymph node (LN) ratio greater than .20 were independent prognostic factors for survival and recurrences. Radicality was most prognostic for survival, and for N+ greater than 4 positive LN for recurrences.
CONCLUSIONS: Radicality and LN ratio are strong prognostic factors. High radicality and adequate nodal assessment are guaranteed by an extended transthoracic approach.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20409512     DOI: 10.1016/j.amjsurg.2009.12.006

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  19 in total

1.  Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection.

Authors:  Po-Kuei Hsu; Bing-Yen Wang; Chien-Sheng Huang; Yu-Chung Wu; Wen-Hu Hsu
Journal:  J Gastrointest Surg       Date:  2011-02-15       Impact factor: 3.452

2.  Prognostic factors in patients with recurrence after complete resection of esophageal squamous cell carcinoma.

Authors:  Xiao-Dong Su; Dong-Kun Zhang; Xu Zhang; Peng Lin; Hao Long; Tie-Hua Rong
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

3.  Treatment Outcomes and Prognostic Factors After Recurrence of Esophageal Squamous Cell carcinoma.

Authors:  Yoichi Hamai; Jun Hihara; Manabu Emi; Takaoki Furukawa; Yuta Ibuki; Ichiko Yamakita; Tomoaki Kurokawa; Morihito Okada
Journal:  World J Surg       Date:  2018-07       Impact factor: 3.352

4.  Significance of thoracoscopy-assisted surgery with a minithoracotomy and hand-assisted laparoscopic surgery for esophageal cancer: the experience of a single surgeon.

Authors:  Chikara Kunisaki; Takashi Kosaka; Hidetaka A Ono; Takashi Oshima; Shoichi Fujii; Ryo Takagawa; Jun Kimura; Motohiko Tokuhisa; Yusuke Izumisawa; Hirochika Makino; Hirotoshi Akiyama; Itaru Endo
Journal:  J Gastrointest Surg       Date:  2011-09-10       Impact factor: 3.452

Review 5.  A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma.

Authors:  M Elshaer; G Gravante; M Kosmin; A Riaz; A Al-Bahrani
Journal:  Ann R Coll Surg Engl       Date:  2016-11-21       Impact factor: 1.891

Review 6.  Siewert III adenocarcinoma: treatment update.

Authors:  Alberto Di Leo; Andrea Zanoni
Journal:  Updates Surg       Date:  2017-03-16

7.  Patterns and influence of nodal metastases after neoadjuvant chemoradiation and R0 resection in esophageal adenocarcinoma.

Authors:  Caitlin A Harrington; Rebecca A Carr; Meier Hsu; Kay See Tan; Smita Sihag; Prasad S Adusumilli; Manjit S Bains; Matthew J Bott; James M Isbell; Bernard J Park; Gaetano Rocco; Valerie W Rusch; David R Jones; Daniela Molena
Journal:  J Thorac Cardiovasc Surg       Date:  2022-03-01       Impact factor: 6.439

8.  Outcomes of lymphadenectomy for lymph node recurrence after esophagectomy or definitive chemoradiotherapy for squamous cell carcinoma of the esophagus.

Authors:  Masayuki Watanabe; Shinji Mine; Kazuhiko Yamada; Hironobu Shigaki; Yoshifumi Baba; Naoya Yoshida; Kiyoshi Kajiyama; Noriko Yamamoto; Takeshi Sano; Hideo Baba
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-06-26

Review 9.  Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis.

Authors:  Shuangjiang Li; Zhiqiang Wang; Jian Huang; Shan Cheng; Heng Du; Guowei Che; Yong Peng
Journal:  BMC Cancer       Date:  2016-11-11       Impact factor: 4.430

10.  Efficacy of intensity-modulated radiotherapy for resected thoracic esophageal squamous cell carcinoma.

Authors:  Wencheng Zhang; Xiao Liu; Zefen Xiao; Lvhua Wang; Hongxing Zhang; Dongfu Chen; Zongmei Zhou; Qinfu Feng; Zhouguang Hui; Jun Liang; Weibo Yin; Jie He
Journal:  Thorac Cancer       Date:  2015-02-02       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.